The Involvement of Post-Translational Modifications in Alzheimer’s Disease

Current Alzheimer Research

Volumn 15, Issue 4, 2018, Pages 313-335

  Marcelli, Serena ^a,b   Corbo, Massimo ^c   Iannuzzi, Filomena ^a   Negri, Lucia ^b   Blandini, Fabio ^d   Nisticò, Robert ^a,e   Feligioni, Marco ^a,c  

^a EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c DEPARTMENT OF NEUROREHABILITATION SCIENCES   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Acetylation; Alzheimer; Nitrosylation; Phosphorylation; Post translational modifications; SUMOylation; Ubiquitinatin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; GENETICS; HUMAN; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TAU PROTEINS;

EID: 85042292035     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205014666170505095109     Document Type: Review

References (322)

1. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 314(5800): 777-81 (2006).
2. Selkoe DJ. The therapeutics of Alzheimer’s disease: Where we stand and where we are heading. Ann Neurol 74(3): 328-36 (2013).
3. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2(8): Pii: A006239 (2012).
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002).
5. Holtzman DM. CSF biomarkers for Alzheimer’s disease: Current utility and potential future use. Neurobiol Aging 32(1): S4-9 (2011).
6. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 377(9770): 1019-31 (2011).
7. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1): A006189 (2011).
8. Nisticò R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G. Targeting synaptic dysfunction in Alzheimer’s disease therapy. Mol Neurobiol 46(3): 572-87 (2012).
9. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dyn amics of gray matter loss in Alzheimer’s disease. J Neurosci Off J Soc Neurosci 23(3): 994-1005 (2003).
10. Mandelkow E-M, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2(7): A006247 (2012).
11. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: A field in its infancy. J Alzheimers Dis 19(1): 355-61 (2010).
12. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2: E167 (2011).
13. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2): 101-12.
14. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2(5): A006270 (2012).
15. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov. Nat Publishing Group 10(9): 698-712 (2011).
16. Lefort R, Pozueta J, Shelanski M. Cross-linking of cell surface amyloid precursor protein leads to increased β-amyloid peptide production in hippocampal neurons: Implications for Alzheimer’s disease. J Neurosci Off J Soc Neurosci 32(31): 10674-85 (2012).
17. Corrigan F, Vink R, Blumbergs PC, Masters CL, Cappai R, van den Heuvel C. sAPPα rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury. J Neurochem 122(1): 208-20 (2012).
18. De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: Structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med 2(1): A006304 (2012).
19. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. J Biol Chem 267(1): 546-54 (1992).
20. Jarrett JT, Lansbury PT. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 3(6): 1055-8 (1993).
21. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat Neurosci 15(3): 349-57 (2012).
22. Kittelberger KA, Piazza F, Tesco G, Reijmers LG. Natural amyloid-β oligomers acutely impair the formation of a contextual fear memory in mice. PloS One 7(1): E29940 (2012).
23. Wei G, Jewett AI, Shea J-E. Structural diversity of dimers of the Alzheimer amyloid-beta(25-35) peptide and polymorphism of the resulting fibrils. Phys Chem Chem Phys 2(14): 3622-9 (2010).
24. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 108(14): 5819-24 (2011).
25. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain J Neurol 133(Pt 5):1328-41 (2010).
26. Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P. SUMO and Alzheimer’s disease. Neuromolecular Med 15(4): 720-36 (2013).
27. Oddo S. The ubiquitin-proteasome system in Alzheimer’s disease. J Cell Mol Med 12(2): 363-73 (2008).
28. Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 423(6938): 435-9 (2003).
29. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol 70(11): 960-9 (2011).
30. Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem 269(39): 24290-7 (1994).
31. Wang L, Brier MR, Snyder AZ, Thomas JB, Fagan AM, Xiong C, et al. Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. JAMA Neurol 70(10): 1242-8 (2013).
32. Wang J-Z, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85(2):148-75 (2008).
33. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J Neurochem 83(1): 176-85 (2002).
34. Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol 15(1): 45-9 (2004).
35. Gerson JE, Castillo-Carranza DL, Kayed R. Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species. ACS Chem Neurosci 5(9): 752-69 (2014).
36. Ingram EM, Spillantini MG. Tau gene mutations: Dissecting the pathogenesis of FTDP-17. Trends Mol Med 8(12): 555-62 (2002).
37. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8(9): 663-72 (2007).
38. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer’s disease ß-amyloid and τ pathologies at synapses. Neurobiol Aging 31(7): 1145-52 (2010).
39. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J Off Publ Fed Am Soc Exp Biol 26(5): 1946-59 (2012).
40. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 78(5): 461-4 (2007).
41. Russell CL, Koncarevic S, Ward MA. Post-translational modifications in Alzheimer’s disease and the potential for new biomarkers. J Alzheimers Dis 41(2): 345-64 (2014).
42. Soderling TR, Derkach VA. Postsynaptic protein phosphorylation and LTP. Trends Neurosci 23(2): 75-80 (2000).
43. DiAntonio A, Hicke L. Ubiquitin-dependent regulation of the synapse. Annu Rev Neurosci 27: 223-46 (2004).
44. Routtenberg A, Rekart JL. Post-translational protein modification as the substrate for long-lasting memory. Trends Neurosci 28(1):12-9 (2005).
45. Lee L, Dale E, Staniszewski A, Zhang H, Saeed F, Sakurai M, et al. Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer’s disease. Sci Rep 4: 7190 (2014).
46. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-59 (2001).
47. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 10: S10-7 (2004).
48. Nisticò R, Ferraina C, Marconi V, Blandini F, Negri L, Egebjerg J, et al. Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer’s disease. Front Pharmacol 5: 63 (2014).
49. Feligioni M, Marcelli S, Knock E, Nadeem U, Arancio O, E Fraser P. SUMO modulation of protein aggregation and degradation. AIMS Mol Sci Aims Press 2(4): 82-410 (2015).
50. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet 30: 405-39 (1996).
51. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82(2): 373-428 (2002).
52. Weissman AM. Regulating protein degradation by ubiquitination. Immunol Today 18(4): 189-98 (1997).
53. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 19(1): 94-102 (2000).
54. de Vrij FMS, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer’s disease by the ubiquitin proteasome system. Prog Neurobiol 74(5): 249-70 (2004).
55. Amm I, Sommer T, Wolf DH. Protein quality control and elimination of protein waste: The role of the ubiquitin-proteasome system. Biochim Biophys Acta 1843(1): 182-96 (2014).
56. Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I. Alzheimer disease: Correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res 639(1): 1-7 (1994).
57. Sugiyama H, Hainfellner JA, Yoshimura M, Budka H. Neocortical changes in Parkinson’s disease, revisited. Clin Neuropathol 13(2): 55-9 (1994).
58. Cammarata S, Caponnetto C, Tabaton M. Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington’s chorea: A pathological correlate of dementia? Neurosci Lett 156(1-2): 96-8 (1993).
59. Schiffer D, Attanasio A, Chiò A, Migheli A, Pezzulo T. Ubiquitinated dystrophic neurites suggest corticospinal derangement in patients with amyotrophic lateral sclerosis. Neurosci Lett 180(1): 21-4 (1994).
60. Mayer RJ, Tipler C, Arnold J, Laszlo L, Al-Khedhairy A, Lowe J, et al. Endosome-lysosomes, ubiquitin and neurodegeneration. Adv Exp Med Biol 389: 61-9 (1996).
61. Bingol B, Sheng M. Deconstruction for reconstruction: The role of proteolysis in neural plasticity and disease. Neuron 69(1): 22-32 (2011).
62. Riederer BM, Leuba G, Vernay A, Riederer IM. The role of the ubiquitin proteasome system in Alzheimer’s disease. Exp Biol Med Maywood 236(3): 268-76 (2011).
63. Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 21(12): 516-20 (1998).
64. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, et al. Inhibition of the ubiquitin-proteasome system in Alzheimer’s disease. Proc Natl Acad Sci USA 97(18): 9902-6 (2000).
65. Hol EM, van Leeuwen FW, Fischer DF. The proteasome in Alzheimer’s disease and Parkinson’s disease: Lessons from ubiquitin B+1. Trends Mol Med 11(11): 488-95 (2005).
66. Metcalfe MJ, Huang Q, Figueiredo-Pereira ME. Coordination between proteasome impairment and caspase activation leading to TAU pathology: Neuroprotection by cAMP. Cell Death Dis 3: E326 (2012).
67. Morel E, Chamoun Z, Lasiecka ZM, Chan RB, Williamson RL, Vetanovetz C, et al. Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat Commun 4: 2250 (2013).
68. El Ayadi A, Stieren ES, Barral JM, Boehning D. Ubiquilin-1 regulates amyloid precursor protein maturation and degradation by stimulating K63-linked polyubiquitination of lysine 688. Proc Natl Acad Sci USA 109(33): 13416-21 (2012).
69. Watanabe T, Hikichi Y, Willuweit A, Shintani Y, Horiguchi T. FBL2 regulates amyloid precursor protein (APP) metabolism by promoting ubiquitination-dependent APP degradation and inhibition of APP endocytosis. J Neurosci Off J Soc Neurosci 32(10): 3352-65 (2012).
70. Kaneko M, Koike H, Saito R, Kitamura Y, Okuma Y, Nomura Y. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. J Neurosci Off J Soc Neurosci 30(11): 3924-32 (2010).
71. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10(12): 524-30 (2000).
72. Dehvari N, Mahmud T, Persson J, Bengtsson T, Graff C, Winblad B, et al. Amyloid precursor protein accumulates in aggresomes in response to proteasome inhibitor. Neurochem Int 60(5): 533-42 (2012).
73. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283(44): 29615-9 (2008).
74. Kourtis N, Tavernarakis N. Cellular stress response pathways and ageing: Intricate molecular relationships. EMBO J 30(13): 2520-31 (2011).
75. Wang H, Saunders AJ. The role of ubiquitin-proteasome in the metabolism of amyloid precursor protein (APP): Implications for novel therapeutic strategies for Alzheimer’s disease. Discov Med 18(97): 41-50 (2014).
76. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent alpha-secretase competes with betasecretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem 275(4): 2568-75 (2000).
77. Yamazaki T, Ihara Y. Effects of specific protease inhibitors on amyloid beta-protein 42 secretion. Neurobiol Aging 19(1): S77-9 (1998).
78. Higaki J, Quon D, Zhong Z, Cordell B. Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14(3): 651-9 (1995).
79. Klafki H, Abramowski D, Swoboda R, Paganetti PA, Staufenbiel M. The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J Biol Chem 271(45): 28655-9 (1996).
80. Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E. Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 180(2):131-43 (2003).
81. Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitinproteasome system. J Neurosci Off J Soc Neurosci 26(16): 4277-88 (2006).
82. Zhao X, Yang J. Amyloid-β peptide is a substrate of the human 20S proteasome. ACS Chem Neurosci 1(10): 655-60 (2010).
83. Rosen KM, Moussa CE-H, Lee H-K, Kumar P, Kitada T, Qin G, et al. Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function. J Neurosci Res 88(1): 167-78 (2010).
84. Wang R, Ying Z, Zhao J, Zhang Y, Wang R, Lu H, et al. Lys(203) and Lys(382) are essential for the proteasomal degradation of BACE1. Curr Alzheimer Res 9(5): 606-15 (2012).
85. Hong L, Huang H-C, Jiang Z-F. Relationship between amyloidbeta and the ubiquitin-proteasome system in Alzheimer’s disease. Neurol Res 36(3): 276-82 (2014).
86. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 281(16): 10825-38 (2006).
87. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Seitelberger F, et al. Tau and ubiquitin immunoreactivity at different stages of formation of Alzheimer neurofibrillary tangles. Prog Clin Biol Res 317: 837-48 (1989).
88. Dammer EB, Na CH, Xu P, Seyfried NT, Duong DM, Cheng D, et al. Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease. J Biol Chem 286(12): 10457-65 (2011).
89. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer’ s disease. Science 235(4796): 1641-4 (1987).
90. Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: The ubiquitinproteasome system versus the autophagy-lysosome system. Prog Neurobiol 105: 49-59 (2013).
91. Delobel P, Leroy O, Hamdane M, Sambo A V, Delacourte A, Buée L. Proteasome inhibition and Tau proteolysis: An unexpected regulation. FEBS Lett 579(1):1-5 (2005).
92. Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttilä T. Proteomic analysis of glial fibrillary acidic protein in Alzheimer’s disease and aging brain. Neurobiol Dis 20(3): 858-70 (2005).
93. Porchet R, Probst A, Bouras C, Dráberová E, Dráber P, Riederer BM. Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer’s disease. Proteomics 3(8): 1476-85 (2003).
94. Riederer IM, Schiffrin M, Kövari E, Bouras C, Riederer BM. Ubiquitination and cysteine nitrosylation during aging and Alzheimer’s disease. Brain Res Bull 80(4-5): 233-41 (2009).
95. Olsen J V, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127(3): 635-48 (2006).
96. Avila J. Tau phosphorylation and aggregation in Alzheimer’s disease pathology. FEBS Lett 580(12): 2922-7 (2006).
97. Noble W, Hanger DP, Miller CCJ, Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 4: 83 (2013).
98. Yu Y, Run X, Liang Z, Li Y, Liu F, Liu Y, et al. Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem 108(6): 1480-94 (2009).
99. Kenessey A, Yen SH. The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. Brain Res 629(1): 40-6 (1993).
100. Braak H, Del Tredici K. Alzheimer’s disease: Intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol Aging 25(6): 713-8 (2004).
101. Zhang Y, Tian Q, Zhang Q, Zhou X, Liu S, Wang J-Z. Hyperphosphorylation of microtubule-associated tau protein plays dual role in neurodegeneration and neuroprotection. Pathophysiol Off J Int Soc Pathophysiol ISP. 16(4): 311-6 (2009).
102. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K. Interaction of tau isoforms with Alzheimer’s disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 276(41): 37967-73 (2001).
103. Buée L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, et al. From tau phosphorylation to tau aggregation: What about neuronal death? Biochem Soc Trans 38(4): 967-72 (2010).
104. Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12(1): 38-55 (2008).
105. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, et al. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285(40): 30851-60 (2010).
106. Gong C-X, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm 112(6): 813-38 (2004).
107. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 5(1): 30-40 (2010).
108. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70(19 Pt 2): 1827-35 (2008).
109. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol 57(5): 721-9 (2005).
110. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci Lett 270(2): 91-4 (1999).
111. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236(2): 262-4 (1997).
112. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20(1-2): 27-39 (2001).
113. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, et al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: Involvement of Src family protein kinases. J Neurosci Off J Soc Neurosci 22(1): 10-20 (2002).
114. Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, et al. Phosphorylation of tau by fyn: Implications for Alzheimer’s disease. J Neurosci 24(9): 2304-12 (2004).
115. Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: Involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem 72(2): 576-84 (1999).
116. Sontag J-M, Sontag E. Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front Mol Neurosci 7: 16 (2014).
117. Plouffe V, Mohamed N-V, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc N. Hyperphosphorylation and cleavage at D421 enhance tau secretion. PloS One 7(5): E36873 (2012).
118. Díaz-Hernández M, Gómez-Ramos A, Rubio A, GómezVillafuertes R, Naranjo JR, Miras-Portugal MT, et al. Tissuenonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem 285(42): 32539-48 (2010).
119. Serenó L, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, et al. A novel GSK-3beta inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol Dis 35(3): 359-67 (2009).
120. Cho J-H, Johnson GVW. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau’s ability to bind and stabilize microtubules. J Neurochem 88(2): 349-58 (2004).
121. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102(19): 6990-5 (2005).
122. Hamdane M, Sambo A-V, Delobel P, Bégard S, Violleau A, Delacourte A, et al. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem 278(36): 34026-34 (2003).
123. Peel AL, Sorscher N, Kim JY, Galvan V, Chen S, Bredesen DE. Tau phosphorylation in Alzheimer’s disease: Potential involvement of an APP-MAP kinase complex. Neuromolecular Med 5(3): 205-18 (2004).
124. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Götz J. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 278(41): 40162-8 (2003).
125. Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14(4): 879-88 (1995).
126. Deng J, Habib A, Obregon DF, Barger SW, Giunta B, Wang Y-J, et al. Soluble amyloid precursor protein alpha (sAPPα) inhibits tau phosphorylation through modulation of GSK3β signaling pathway. J Neurochem 135(3): 630-7 (2015).
127. Gibb GM, Pearce J, Betts JC, Lovestone S, Hoffmann MM, Maerz W, et al. Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3 beta identified by nano-electrospray mass spectrometry. FEBS Lett 485(2-3): 99-103 (2000).
128. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA 98(15): 8838-43 (2001).
129. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 33(9): 1194-9 (2002).
130. Lee H-G, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer’s disease: Pathogen or protector? Trends Mol Med 11(4): 164-9 (2005).
131. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60(8): 759-67 (2001).
132. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PLR, Shimohama S, et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 277(7): 4644-8 (2002).
133. Gómez-Ramos A, Díaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 71(6): 863-70 (2003).
134. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer’s disease. J Neurochem 76(2): 435-41 (2001).
135. Arendt T, Stieler J, Strijkstra AM, Hut RA, Rüdiger J, Van der Zee EA, et al. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci Off J Soc Neurosci 23(18): 697281 (2003).
136. Zhou F, Zhu X, Castellani RJ, Stimmelmayr R, Perry G, Smith MA, et al. Hibernation, a model of neuroprotection. Am J Pathol 158(6): 2145-51 (2001).
137. Kumar S, Walter J. Phosphorylation of amyloid beta (Aβ) peptides a trigger for formation of toxic aggregates in Alzheimer’s disease. Aging 3(8): 803-12 (2011).
138. Kikuchi A, Yamamoto H, Kishida S. Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal 19(4): 659-71 (2007).
139. Eun Jeoung L, Sung Hee H, Jaesun C, Sung Hwa S, Kwang Hum Y, Min Kyoung K, et al. Regulation of glycogen synthase kinase 3beta functions by modification of the small ubiquitin-like modifier. Open Biochem J 67-76 (2008).
140. Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29(2): 95-102 (2004).
141. Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 99(2): 305-16 (2000).
142. Hartigan JA, Johnson GV. Transient increases in intracellular calcium result in prolonged site-selective increases in tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J Biol Chem 274(30): 21395-401 (1999).
143. Ishii T, Furuoka H, Muroi Y, Nishimura M. Inactivation of integrin-linked kinase induces aberrant tau phosphorylation via sustained activation of glycogen synthase kinase 3beta in N1E-115 neuroblastoma cells. J Biol Chem 278(29): 26970-5 (2003).
144. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 31(1): 33-40 (2011).
145. Hutchins AP, Diez D, Miranda-Saavedra D. Genomic and computational approaches to dissect the mechanisms of STAT3’s universal and cell type-specific functions. JAK-STAT 2(4): E25097 (2013).
146. Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity 36(4): 503-14 (2012).
147. Wan J, Fu AKY, Ip FCF, Ng H-K, Hugon J, Page G, et al. Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: Implications in Alzheimer’s disease. J Neurosci Off J Soc Neurosci 30(20): 6873-81 (2010).
148. Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Gao F, et al. Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PloS One 8(4): E61462 (2013).
149. Xiong J, Wang C, Chen H, Hu Y, Tian L, Pan J, et al. Aβ-induced microglial cell activation is inhibited by baicalin through the JAK2/STAT3 signaling pathway. Int J Neurosci 124(8): 609-20 (2014).
150. Zhang Z, Wu Z, Zhu X, Hui X, Pan J, Xu Y. Hydroxy-safflor yellow A inhibits neuroinflammation mediated by Aβ1-42 in BV-2 cells. Neurosci Lett 562: 39-44 (2014).
151. Murase S, McKay RD. Neuronal activity-dependent STAT3 localization to nucleus is dependent on Tyr-705 and Ser-727 phosphorylation in rat hippocampal neurons. Eur J Neurosci 39(4): 557-65 (2014).
152. Eufemi M, Cocchiola R, Romaniello D, Correani V, Di Francesco L, Fabrizi C, et al. Acetylation and phosphorylation of STAT3 are involved in the responsiveness of microglia to beta amyloid. Neurochem Int 81: 48-56 (2015).
153. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship?. Ann NY Acad Sci 1171: 59-76 (2009).
154. Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, et al. Suppression of eIF2α kinases alleviates Alzheimer’s diseaserelated plasticity and memory deficits. Nat Neurosci 16(9): 1299-305 (2013).
155. Chow WNV, Ngo JCK, Li W, Chen YW, Tam KMV, Chan HYE, et al. Phosphorylation of FE65 Ser610 by serumand glucocorticoid-induced kinase 1 modulates Alzheimer’s disease amyloid precursor protein processing. Biochem J 470(3): 303-17 (2015).
156. Martin S, Wilkinson KA, Nishimune A, Henley JM. Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nat Rev Neurosci 8(12): 948-59 (2007).
157. Feligioni M, Brambilla E, Camassa A, Sclip A, Arnaboldi A, Morelli F, et al. Crosstalk between JNK and SUMO signaling pathways: DeSUMOylation is protective against H2O2-induced cell injury. PloS One 6(12): E28185 (2011).
158. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 73: 355-82 (2004).
159. Feligioni M, Nisticò R. SUMO: A (oxidative) stressed protein. Neuromolecular Med 15(4): 707-19 (2013).
160. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol. 8(12): 947-56 (2007).
161. Ahn K, Song JH, Kim DK, Park MH, Jo SA, Koh YH. Ubc9 gene polymorphisms and late-onset Alzheimer’s disease in the Korean population: A genetic association study. Neurosci Lett 465(3): 2725 (2009).
162. McMillan LE, Brown JT, Henley JM, Cimarosti H. Profiles of SUMO and ubiquitin conjugation in an Alzheimer’s disease model. Neurosci Lett 502(3): 201-8 (2011).
163. Zhang Y-Q, Sarge KD. Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels. Biochem Biophys Res Commun 374(4): 673-8 (2008).
164. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 276(38): 35368-74 (2001).
165. Li Y, Wang H, Wang S, Quon D, Liu Y-W, Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc Natl Acad Sci USA 100(1): 259-64 (2003).
166. Dorval V, Mazzella MJ, Mathews PM, Hay RT, Fraser PE. Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem J 404(2): 30916 (2007).
167. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1(5): 345-7 (1992).
168. Sarge KD, Park-Sarge O-K. Sumoylation and human disease pathogenesis. Trends Biochem Sci 34(4): 200-5 (2009).
169. Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med 2(7): A006338 (2012).
170. Yun S-M, Cho S-J, Song JC, Song SY, Jo SA, Jo C, et al. SUMO1 modulates Aβ generation via BACE1 accumulation. Neurobiol Aging 34(3): 650-62 (2013).
171. Yang Q-G, Wang F, Zhang Q, Xu W-R, Chen Y-P, Chen G-H. Correlation of increased hippocampal Sumo3 with spatial learning ability in old C57BL/6 mice. Neurosci Let 518(2): 75-9 (2012).
172. Matsuzaki S, Lee L, Knock E, Srikumar T, Sakurai M, Hazrati LN, et al. SUMO1 affects synaptic function, spine density and memory. Sci Rep 5:10730 (2015).
173. Dorval V, Fraser PE. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 281(15): 9919-24 (2006).
174. Luo H-B, Xia Y-Y, Shu X-J, Liu Z-C, Feng Y, Liu X-H, et al. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci USA 111(46): 16586-91 (2014).
175. Takahashi K, Ishida M, Komano H, Takahashi H. SUMO-1 immunoreactivity co-localizes with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. Neurosci Lett 441(1): 90-3 (2008).
176. Dorval V, Fraser PE. SUMO on the road to neurodegeneration. Biochim Biophys Acta 1773(6): 694-706 (2007).
177. Pountney D, Huang Y, Burns R, Haan E, Thompson P, Blumbergs P, et al. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp Neurol 184(1): 436-46 (2003).
178. Sarge KD, Park-Sarge O-K. SUMO and its role in human diseases. Int Rev Cell Mol Biol 288: 167-83 (2011).
179. Mattson MP. Neuronal death and GSK-3β: A tau fetish? Trends Neurosci 24(5): 255-6 (2001).
180. Cho B, Choi SY, Cho HM, Kim HJ, Sun W. Physiological and pathological significance of dynamin-related protein 1 (drp1)-dependent mitochondrial fission in the nervous system. Exp Neurobiol 22(3): 149-57 (2013).
181. Wang X, Su B, Lee H, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci Off J Soc Neurosci 29(28): 9090-103 (2009).
182. Harder Z, Zunino R, McBride H. Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr Biol 14(4): 340-5 (2004).
183. Figueroa-Romero C, Iñiguez-Lluhí JA, Stadler J, Chang C-R, Arnoult D, Keller PJ, et al. SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. FASEB J Off Publ Fed Am Soc Exp Biol 23(11): 3917-27 (2009).
184. Braschi E, Zunino R, McBride HM. MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission. EMBO Rep 10(7): 748-54 (2009).
185. Wasiak S, Zunino R, McBride HM. Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. J Cell Biol 177(3): 439-50 (2007).
186. Prudent J, Zunino R, Sugiura A, Mattie S, Shore GC, McBride HM. MAPL SUMOylation of Drp1 Stabilizes an ER/Mitochondrial Platform Required for Cell Death. Mol Cell 59(6): 941-55 (2015).
187. Weeraratna AT, Kalehua A, Deleon I, Bertak D, Maher G, Wade MS, et al. Alterations in immunological and neurological gene expression patterns in Alzheimer’s disease tissues. Exp Cell Res 313(3): 450-61 (2007).
188. Guo C, Hildick KL, Luo J, Dearden L, Wilkinson KA, Henley JM. SENP3-mediated deSUMOylation of dynamin-related protein 1 promotes cell death following ischaemia. EMBO J 32(11): 1514-28 (2013).
189. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1): A006346 (2012).
190. Hoppe JB, Rattray M, Tu H, Salbego CG, Cimarosti H. SUMO-1 conjugation blocks beta-amyloid-induced astrocyte reactivity. Neurosci Lett 546: 51-6 (2013).
191. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437(7059): 75963 (2005).
192. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin M-E, Willson TM, et al. Parallel SUMOylation-dependent pathways mediate geneand signal-specific transrepression by LXRs and PPARgamma. Mol Cell 25(1): 57-70 (2007).
193. Shalizi A, Gaudillière B, Yuan Z, Stegmüller J, Shirogane T, Ge Q, et al. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311(5763): 1012-7 (2006).
194. Martin S, Nishimune A, Mellor JR, Henley JM. SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature 447(7142): 321-5 (2007).
195. Chao H-W, Hong C-J, Huang T-N, Lin Y-L, Hsueh Y-P. SUMOylation of the MAGUK protein CASK regulates dendritic spinogenesis. J Cell Biol 182(1): 141-55 (2008).
196. Craig TJ, Henley JM. SUMOylation, Arc and the regulation homeostatic synaptic scaling: Implications in health and disease. Commun Integr Biol 5(6): 634-6 (2012).
197. Feligioni M, Nishimune A, Henley JM. Protein SUMOylation modulates calcium influx and glutamate release from presynaptic terminals. Eur J Neurosci 29(7): 1348-56 (2009).
198. Dadke S, Cotteret S, Yip S-C, Jaffer ZM, Haj F, Ivanov A, et al. Regulation of protein tyrosine phosphatase 1B by sumoylation. Nat Cell Biol 9(1): 80-5 (2007).
199. Giorgino F, de Robertis O, Laviola L, Montrone C, Perrini S, McCowen KC, et al. The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. Proc Natl Acad Sci USA 97(3): 1125-30 (2000).
200. Comerford KM, Leonard MO, Karhausen J, Carey R, Colgan SP, Taylor CT. Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proc Natl Acad Sci USA 100(3): 986-91 (2003).
201. Stilling RM, Fischer A. The role of histone acetylation in ageassociated memory impairment and Alzheimer’s disease. Neurobiol Learn Mem 96(1): 19-26 (2011).
202. Norris KL, Lee J-Y, Yao T-P. Acetylation goes global: The emergence of acetylation biology. Sci Signal 2(97): Pe76 (2009).
203. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23(4): 607-18 (2006).
204. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and coregulates major cellular functions. Science 325(5942): 834-40 (2009).
205. Lin H, Su X, He B. Protein lysine acylation and cysteine succination by intermediates of energy metabolism. ACS Chem Biol 7(6): 947-60 (2012).
206. Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: The road ahead. Front Pharmacol 3: 4 2012
207. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327(5968): 1000-4 (2010).
208. Marshall KE, Morris KL, Charlton D, O’Reilly N, Lewis L, Walden H, et al. Hydrophobic, aromatic, and electrostatic interactions play a central role in amyloid fibril formation and stability. Biochemistry (Mosc). Am Chem Soc 50(12): 2061-71 (2011).
209. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6): 953-66 (2010).
210. Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet Aug 23(1): 104-16 (2013).
211. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commu 2: 252 (2011).
212. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM-Y, et al. Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain J Neurol 135(Pt 3): 807-18 (2012).
213. Cook C, Stankowski JN, Carlomagno Y, Stetler C, Petrucelli L. Acetylation: A new key to unlock tau’s role in neurodegeneration. Alzheimers Res Ther 6(3): 29 (2014).
214. Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, et al. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet 21(13): 2936-45 (2012).
215. Dickey CA, Koren J, Zhang Y-J, Xu Y-F, Jinwal UK, Birnbaum MJ, et al. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci USA 105(9): 3622-7 (2008).
216. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11(1): 153-63 (1993).
217. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117(3): 648-58 (2007).
218. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116(5): 671-82 (2004).
219. Augustinack JC, Schneider A, Mandelkow E-M, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol (Berl) 103(1): 26-35 (2002).
220. Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron 78(1): 94-108 (2013).
221. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schlüter OM, Bradke F, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease. EMBO Mol Med 5(1): 52-63 (2013).
222. Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ. HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc Natl Acad Sci USA 110(12): 4604-9 (2013)
223. Dompierre JP, Godin JD, Charrin BC, Cordelières FP, King SJ, Humbert S, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation. J Neurosci Off J Soc Neurosci 27(13): 3571-83 (2007).
224. Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van Damme P, et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum Mol Genet 22(9): 1783-90 (2013).
225. Iqbal K, Liu F, Gong C-X, Alonso ADC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (Berl) 118(1): 53-69 (2009).
226. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, et al Microtubule reduction in Alzheimer’s disease and aging is independent of tau filament formation. Am J Pathol 162(5): 1623-7 (2003).
227. Zhang F, Su B, Wang C, Siedlak SL, Mondragon-Rodriguez S, Lee H-G, et al. Posttranslational modifications of α-tubulin in alzheimer disease. Transl Neurodegener 4: 9 (2015).
228. Hempen B, Brion JP. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer’s disease. J Neuropathol Exp Neurol 55(9): 964-72 (1996).
229. L’Hernault SW, Rosenbaum JL. Chlamydomonas.alpha.-tubulin is posttranslationally modified by acetylation on the.epsilon.-amino group of a lysine. Biochemistry (Mosc). Am Chem Soc 24(2):473-8 (1985).
230. Kull FJ, Sloboda RD. A slow dance for microtubule acetylation. Cell 157(6): 1255-6 (2014).
231. Cueva JG, Hsin J, Huang KC, Goodman MB. Posttranslational acetylation of α-tubulin constrains protofilament number in native microtubules. Curr Biol 22(12):1066-74 (2012).
232. Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL, et al. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PloS One 7(8): E42983 (2012).
233. Mackeh R, Lorin S, Ratier A, Mejdoubi-Charef N, Baillet A, Bruneel A, et al. Reactive oxygen species, AMP-activated protein kinase, and the transcription cofactor p300 regulate α-tubulin acetyltransferase-1 (αTAT-1/MEC-17)-dependent microtubule hyperacetylation during cell stress. J Biol Chem 289(17): 11816-28 (2014).
234. Giustiniani J, Daire V, Cantaloube I, Durand G, Poüs C, Perdiz D, et al. Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53. Cell Signal 21(4): 529-39 (2009).
235. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 35(4): 870-80 (2010).
236. Zhuang S. Regulation of STAT signaling by acetylation. Cell Signal 25(9): 1924-31 (2013).
237. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379(6566): 645-8 (1996).
238. Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nat Rev Neurosci 6(2):108-18 (2005).
239. Sananbenesi F, Fischer A. The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biol Chem 390(11): 1145-53 (2009).
240. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 403(6765): 41-5 (2000).
241. Winter S, Fischle W. Epigenetic markers and their cross-talk. Essays Biochem 48(1): 45-61 (2010).
242. Fischer A, Sananbenesi F, Mungenast A, Tsai L-H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31(12): 605-17 (2010).
243. Levenson JM, O’Riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 279(39): 40545-59 (2004).
244. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai L-H. Recovery of learning and memory is associated with chromatin remodelling. Nature 447(7141):178-82 (2007).
245. Koshibu K, Graff J, Beullens M, Heitz FD, Berchtold D, Russig H, et al. Protein Phosphatase 1 Regulates the Histone Code for LongTerm Memory. J Neurosci 29(41):13079-89 (2009).
246. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 7;328(5979):753-6 (2010).
247. Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H, Kirsch W. Targeted proteomics for quantification of histone acetylation in Alzheimer’s disease. Proteomics 12(8): 1261-8 (2012).
248. Ricobaraza A, Cuadrado-Tejedor M, Garcia-Osta A. Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Abeta. Front Biosci Elite Ed 3:1375-84 (2011).
249. Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459(7243): 55-60 (2009).
250. Gong B, Vitolo O V, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114(11): 1624-34 (2004).
251. Francis YI, Fà M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer’s disease. J Alzheimers Dis 18(1): 1319 (2009).
252. Zhao Q-F, Yu J-T, Tan L. S-Nitrosylation in Alzheimer’s disease. Mol Neurobiol 51(1): 268-80 (2015).
253. Nakamura T, Tu S, Akhtar MW, Sunico CR, Okamoto S-I, Lipton SA. Aberrant protein s-nitrosylation in neurodegenerative diseases. Neuron 78(4):596-614 (2013).
254. Ghafourifar P, Bringold U, Klein SD, Richter C. Mitochondrial nitric oxide synthase, oxidative stress and apoptosis. Biol Signals Recept 10(1-2): 57-65 (2013).
255. Stamler JS, Lamas S, Fang FC. Nitrosylation. The prototypic redox-based signaling mechanism. Cell 106(6): 675-83 (2001).
256. Förstermann U, Schmidt HH, Pollock JS, Sheng H, Mitchell JA, Warner TD, et al. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem Pharmacol 42(10): 1849-57 (1991).
257. Ho GPH, Selvakumar B, Mukai J, Hester LD, Wang Y, Gogos JA, et al. S-nitrosylation and S-palmitoylation reciprocally regulate synaptic targeting of PSD-95. Neuron 71(1):131-41 (2011).
258. Fukui H, Moraes CT. The mitochondrial impairment, oxidative stress and neurodegeneration connection: Reality or just an attractive hypothesis? Trends Neurosci 31(5): 251-6 (2008).
259. Zaręba-Kozioł M, Szwajda A, Dadlez M, Wysłouch-Cieszyńska A, Lalowski M. Global analysis of S-nitrosylation sites in the wild type (APP) transgenic mouse brain-clues for synaptic pathology. Mol Cell Proteomics 13(9): 2288-305 (2014).
260. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AMG. Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity. Nat Rev Neurosci 8(10): 766-75 (2007).
261. Knott AB, Bossy-Wetzel E. Nitric oxide in health and disease of the nervous system. Antioxid Redox Signal 11(3): 541-54 (2009).
262. Graves DB. The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology. J Phys Appl Phys IOP Publishing 45(26): 263001 (2012).
263. Wilkins HM, Kirchhof D, Manning E, Joseph JW, Linseman DA. Mitochondrial glutathione transport is a key determinant of neuronal susceptibility to oxidative and nitrosative stress. J Biol Chem 288(7): 5091-101 (2013).
264. Jeon GS, Nakamura T, Lee J-S, Choi W-J, Ahn S-W, Lee K-W, et al. Potential effect of S-nitrosylated protein disulfide isomerase on mutant SOD1 aggregation and neuronal cell death in amyotrophic lateral sclerosis. Mol Neurobiol 49(2): 796-807 (2014).
265. Xue Y, Liu Z, Gao X, Jin C, Wen L, Yao X, et al. GPS-SNO: Computational prediction of protein S-nitrosylation sites with a modified GPS algorithm. PloS One 5(6): E11290 (2010).
266. Zahid S, Khan R, Oellerich M, Ahmed N, Asif AR. Differential Snitrosylation of proteins in Alzheimer’s disease. Neuroscience 256: 126-36 (2014).
267. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123): 921-3 (1993).
268. Arold S, Sullivan P, Bilousova T, Teng E, Miller CA, Poon WW, et al. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer’s disease and apoE TR mouse cortex. Acta Neuropathol (Berl) 23(1): 39-52 (2011).
269. Abrams AJ, Farooq A, Wang G. S-nitrosylation of ApoE in Alzheimer’s disease. Biochemistry (Mosc). Am Chem Soc 50(17): 3405-7 (2011).
270. Oikawa N, Hatsuta H, Murayama S, Suzuki A, Yanagisawa K. Influence of APOE genotype and the presence of Alzheimer’s pathology on synaptic membrane lipids of human brains. J Neurosci Res 92(5): 641-50 (2014).
271. Colton CA, Brown CM, Czapiga M, Vitek MP. Apolipoprotein-E allele-specific regulation of nitric oxide production. Ann NY Acad Sci 962: 212-25 (2002).
272. Lu R-C, Wang H, Tan M-S, Yu J-T, Tan L. TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer’s disease in Han Chinese. J Neural Transm Vienna Austria 121(3): 283-7 (2014).
273. Cheung ZH, Ip NY. Cdk5: A multifaceted kinase in neurodegenerative diseases. Trends Cell Biol 22(3): 169-75 (2012).
274. Qu J, Nakamura T, Holland EA, McKercher SR, Lipton SA. Snitrosylation of Cdk5: Potential implications in amyloid-β-related neurotoxicity in Alzheimer disease. Prion 6(4): 364-70 (2012).
275. Qu J, Nakamura T, Cao G, Holland EA, McKercher SR, Lipton SA. S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide. Proc Natl Acad Sci USA 108(34): 14330-5 (2011).
276. Zhang P, Yu P-C, Tsang AHK, Chen Y, Fu AKY, Fu W-Y, et al. S-nitrosylation of cyclin-dependent kinase 5 (cdk5) regulates its kinase activity and dendrite growth during neuronal development. J Neurosci Off J Soc Neurosci 30(43): 14366-70 (2010).
277. Song Y, Brady ST. Post-translational modifications of tubulin: Pathways to functional diversity of microtubules. Trends Cell Biol 25(3): 125-36 (2015).
278. Kamnev A, Muhar M, Preinreich M, Ammer H, Propst F. Difficulties in generating specific antibodies for immunohistochemical detection of nitrosylated tubulins. PloS One 8(6): E68168 (2013).
279. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A 107(43): 18670-5 (2010).
280. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med 14(2): 45-53 (2008).
281. Cho D-H, Nakamura T, Fang J, Cieplak P, Godzik A, Gu Z, et al. S-Nitrosylation of drp1 mediates -amyloid-related mitochondrial fission and neuronal injury. Science 324(5923):102-5 (2009).
282. Sato N, Morishita R. Plasma Aβ: A possible missing link between Alzheimer disease and diabetes. Diabetes 62(4): 1005-6 (2013).
283. Ito S, Ohtsuki S, Murata S, Katsukura Y, Suzuki H, Funaki M, et al. Involvement of insulin-degrading enzyme in insulinand atrial natriuretic peptide-sensitive internalization of amyloid-β peptide in mouse brain capillary endothelial cells. J Alzheimers Dis 38(1): 185-200 (2014).
284. Kruszelnicka O. Nitric oxide vs insulin secretion, action and clearance. Diabetologia 57(1): 257-8 (2014).
285. Ralat LA, Ren M, Schilling AB, Tang W-J. Protective role of Cys178 against the inactivation and oligomerization of human insulindegrading enzyme by oxidation and nitrosylation. J Biol Chem 284(49): 34005-18 (2009).
286. Tortosa E, Galjart N, Avila J, Sayas CL. MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J 32(9): 1293-306 (2013).
287. Stroissnigg H, Trancíková A, Descovich L, Fuhrmann J, Kutschera W, Kostan J, et al. S-nitrosylation of microtubule-associated protein 1B mediates nitric-oxide-induced axon retraction. Nat Cell Biol 9(9): 1035-45 (2007).
288. Sen N, Hara MR, Kornberg MD, Cascio MB, Bae B-I, Shahani N, et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol 10(7): 866-73 (2008).
289. Lee SB, Kim CK, Lee K-H, Ahn J-Y. S-nitrosylation of B23/nucleophosmin by GAPDH protects cells from the SIAH1GAPDH death cascade. J Cell Biol 199(1): 65-76 (2012).
290. Jia J, Arif A, Willard B, Smith JD, Stuehr DJ, Hazen SL, et al. Protection of extraribosomal RPL13a by GAPDH and dysregulation by S-nitrosylation. Mol Cell 47(4): 656-63 (2012).
291. Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum Mol Genet 21(23): 5131-46 (2012).
292. Arbel N, Shoshan-Barmatz V. Voltage-dependent anion channel 1based peptides interact with Bcl-2 to prevent antiapoptotic activity. J Biol Chem 285(9): 6053-62 (2010).
293. Hyman BT, Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved 13(6): 395-406 (2012).
294. Yoo BC, Fountoulakis M, Cairns N, Lubec G. Changes of voltagedependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer’s disease and Down syndrome. Electrophoresis 22(1): 172-9 (2001).
295. Shi Z-Q, Sunico CR, McKercher SR, Cui J, Feng G-S, Nakamura T, et al. S-nitrosylated SHP-2 contributes to NMDA receptormediated excitotoxicity in acute ischemic stroke. Proc Natl Acad Sci USA 110(8): 3137-42 (2013).
296. Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen HS, et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci 3(1):15-21 (2000).
297. Takahashi H, Shin Y, Cho S-J, Zago WM, Nakamura T, Gu Z, et al. Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif. Neuron 53(1): 53-64 (2007).
298. Nakamura T, Lipton SA. Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: Possible pharmacological strategies. Cell Calcium 47(2): 190-7 (2010).
299. Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA 110(27): E2518-27 (2013).
300. Beltrao P, Bork P, Krogan NJ, van Noort V. Evolution and functional cross-talk of protein post-translational modifications. Mol Syst Biol 9: 714 (2013).
301. Yang X-J, Seto E. Lysine acetylation: Codified crosstalk with other posttranslational modifications. Mol Cell 31(4): 449-61 (2008).
302. Choudhary C, Mann M. Decoding signalling networks by mass spectrometry-based proteomics. Nat Rev Mol Cell Biol 11(6): 427-39 (2010).
303. Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181(4): 1426-35 (2012).
304. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279(6): 4869-76 (2004).
305. Luna-Muñoz J, Chávez-Macías L, García-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease. J Alzheimers Dis 12(4): 365-75 (2007).
306. Mondragón-Rodríguez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI, Avila J, et al. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer’s disease. Int J Exp Pathol 89(2): 81-90 (2008).
307. García-Sierra F, Jarero-Basulto JJ, Kristofikova Z, Majer E, Binder LI, Ripova D. Ubiquitin is associated with early truncation of tau protein at aspartic acid(421) during the maturation of neurofibrillary tangles in Alzheimer’s disease. Brain Pathol Zurich Switz 22(2): 240-50 (2012).
308. Dickey CA, Yue M, Lin W-L, Dickson DW, Dunmore JH, Lee WC, et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phosphoand caspase-3-cleaved tau species. J Neurosci Off J Soc Neurosci 26(26): 6985-96 (2006).
309. Stoothoff WH, Johnson GVW. Tau phosphorylation: Physiological and pathological consequences. Biochim Biophys Acta 1739(2-3): 280-97 (2005).
310. Kopke E, Tung Y, Shaikh S, Alonso A, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a nonpaired helical filament pool in Alzheimer disease. J Biol Chem 268(32): 24374-84 (1993).
311. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem 85(1): 115-22 (2003).
312. Ulrich HD. Mutual interactions between the SUMO and ubiquitin systems: A plea of no contest. Trends Cell Biol 15(10): 525-32 (2005).
313. Manetto V, Perry G, Tabaton M, Mulvihill P, Fried VA, Smith HT, et al. Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci USA 85(12): 4501-5 (1988).
314. Grune T, Botzen D, Engels M, Voss P, Kaiser B, Jung T, et al. Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch Biochem Biophys 500(2): 181-8 (2010).
315. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13(7): 703-14 (2004).
316. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10(6):1151-60 (1993).
317. Fukuda I, Ito A, Hirai G, Nishimura S, Kawasaki H, Saitoh H, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol 16(2): 133-40 (2009).
318. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer’s disease. J Biol Chem 275(8): 5535-44 (2000).
319. Kimura T, Fukuda T, Sahara N, Yamashita S, Murayama M, Mizoroki T, et al. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem 285(49): 38692-9 (2010).
320. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 2(2): 233-9 (1998).
321. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N, Bennett DA, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68(1): 48-58 (2009).
322. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733): 476-81 (2005).